Management and control strategies for community-associated methicillin-resistant Staphylococcus aureus

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 9, 2008, Pages 1463-1479

  Avdic, Edina ^a   Cosgrove, Sara E ^b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

CA MRSA; Clindamycin; Community associated methicillin resistant Staphylococcus aureus; Community associated MRSA; Daptomycin; Doxycycline; Fluoroquinolones; Linezolid; Minocycline; MRSA; Panton Valentine leucocidin; Rifampin; Tetracyclines; Tigecycline; Trimethoprim sulfamethoxazole; Vancomycin

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFALEXIN; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; DICLOXACILLIN; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MINOCYCLINE; MOXIFLOXACIN; ORAL CONTRACEPTIVE AGENT; ORITAVANCIN; PENICILLIN G; PLACEBO; PROTEINASE INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TELAVANCIN; TETRACYCLINE; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN; WARFARIN; ANTIINFECTIVE AGENT;

ADJUVANT THERAPY; ANTIBIOTIC SENSITIVITY; BACTERIAL COLONIZATION; BACTERIAL ENDOCARDITIS; BODY FLUID; BONE GROWTH; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COLITIS; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG COST; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SYNTHESIS; ENAMEL HYPOPLASIA; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERKALEMIA; INFECTION CONTROL; INTENSIVE CARE; LACTIC ACIDOSIS; LIVER FUNCTION TEST; LIVER TOXICITY; LOW DRUG DOSE; MEDLINE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONOTHERAPY; NAUSEA AND VOMITING; NECROTIZING FASCIITIS; NEUROPATHY; OPTIC NEURITIS; PHOTOSENSITIVITY; PNEUMONIA; RED MAN SYNDROME; REVIEW; RISK FACTOR; SEROTONIN SYNDROME; SIDE EFFECT; SKIN ABSCESS; SKIN INFECTION; SKIN NECROSIS; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION; SUPPURATION; SYMPTOM; THROMBOCYTOPENIA; TOOTH DISCOLORATION; WOUND CARE; WOUND DRAINAGE; COMMUNICABLE DISEASE; DRUG EFFECT; ISOLATION AND PURIFICATION; MICROBIOLOGY; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

EID: 46749150620     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.9.1463     Document Type: Review

References (119)

1. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus - Minnesota and North Dakota, 1997 - 1999. MMWR Morb Mortal Wkly Rep 1999;48:707-10
2. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007;298:1763-71
3. Saiman L, O'Keefe M, Graham PL III, et al. Hospital transmission of community-acquired methicillin-resistant Staphylococcus aureus among postpartum women. Clin Infect Dis 2003;37:1313-9
4. Kourbatova EV, Halvosa JS, King MD, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA 300 clone as a cause of health care-associated infections among patients with prosthetic joint infections. Am J Infect Control 2005;33:385-91
5. Seybold U, Kourbatova EV, Johnson JG, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin Infect Dis 2006;42:647-56
6. Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003;290:2976-84
7. Crum NF, Lee RU, Thornton SA, et al. Fifteen-year study of the changing epidemiology of methicillin-resistant Staphylococcus aureus. Am J Med 2006;119:943-51
8. Ellis MW, Hospenthal DR, Dooley DP, et al. Natural history of community-acquired methicillin-resistant Staphylococcus aureus colonization and infection in soldiers. Clin Infect Dis 2004;39:971-9
9. Lowy FD, Aiello AE, Bhat M, et al. Staphylococcus aureus colonization and infection in New York state prisons. J Infect Dis 2007;196:911-8
10. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006;355:666-74
11. Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005;352:1436-44
12. Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005;352:1445-53
13. Pannaraj PS, Hulten KG, Gonzalez BE, et al. Infective pyomyositis and myositis in children in the era of community-acquired, methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2006;43:953-60
14. Gonzalez BE, Martinez-Aguilar G, Hulten KG, et al. Severe Staphylococcal sepsis in adolescents in the era of community-acquired methicillin-resistant Staphylococcus aureus. Pediatrics 2005;115:642-8
15. Adem PV, Montgomery CP, Husain AN, et al. Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children. N Engl J Med 2005;353:1245-51
16. Mongkolrattanothai K, Boyle S, Kahana MD, Daum RS. Severe Staphylococcus aureus infections caused by clonally related community-acquired methicillin-susceptible and methicillin-resistant isolates. Clin Infect Dis 2003;37:1050-8
17. Fitch MT, Manthey DE, McGinnis HD, et al. Videos in clinical medicine. Abscess incision and drainage. N Engl J Med 2007;357:e20
18. Hankin A, Everett WW. Are antibiotics necessary after incision and drainage of a cutaneous abscess? Ann Emerg Med 2007;50:49-51
19. Rajendran PM, Young DM, Maurer T, et al. Antibiotic use in the treatment of soft tissue abscesses: a survey of current practice. Surg Infect (Larchmt) 2007;8:237-8
20. Lee MC, Rios AM, Aren MF, et al. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J 2004;23:123-7
21. Young DM, Harris HW, Charlebois ED, et al. An epidemic of methicillin-resistant Staphylococcus aureus soft tissue infections among medically underserved patients. Arch Surg 2004;139:947-51; discussion 951-3
22. Miller LG, Quan C, Shay A, et al. A prospective investigation of outcomes after hospital discharge for endemic, community-acquired methicillin-resistant and -susceptible Staphylococcus aureus skin infection. Clin Infect Dis 2007;44:483-92
23. Rajendran PM, Young D, Maurer T, et al. Randomised, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother 2007;51:4044-8
24. Ruhe JJ, Smith N, Bradsher RW, Menon A. Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome. Clin Infect Dis 2007;44:777-84
25. Gorwitz RJ, Jernigan DB, Powers JH, Jernigan JA; Participants in the CDC Convened Experts' Meeting on Management of MRSA in the Community. Strategies for clinical management of MRSA in the community: summary of an experts' meeting convened by the Centers for Disease Control and Prevention. 2006. Available from: http://www.cdc.gov/ncidod/dhqp/ ar_mrsa_html [Last accessed 3rd May 2008]
26. Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. J Am Dent Assoc 2007;138:739-45, 747-60
27. Schneider-Lindner V, Delaney J, Dial S, et al. Antimicrobial drugs and community-acquired methicillin-resistant Staphylococcus aureus, United Kingdom. Emerg Infect Dis 2007;13:994-1000
28. Han LL, McDougal LK, Gorwitz RJ, et al. High frequencies of clindamycin and tetracycline resistance in methicillin-resistant Staphylococcus aureus pulsed-field type USA300 isolates collected at a Boston ambulatory health center. J Clin Microbiol 2007;45:1350-2
29. Kaka AS, Rueda AM, Shelburne SA III, et al. Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006;58:680-3
30. Szumowski JD, Cohen DE, Kanaya F, Mayer KH. Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic. Antimicrob Agents Chemother 2007;51:423-8
31. Stein A, Bataille JF, Drancourt M, et al. Ambulatory treatment of multidrug-resistant Staphylococcus-infected orthopedic implants with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole). Antimicrob Agents Chemother 1998;42:3086-91
32. Iyer S, Jones DH. Community-acquired methicillin-resistant Staphylococcus aureus skin infection: a retrospective analysis of clinical presentation and treatment of a local outbreak. J Am Acad Dermatol 2004;50:854-8
33. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992;117:390-8
34. Kaplan SL, Hulten KG, Gonzalez BE, et al. Three-year surveillance of community-acquired Staphylococcus aureus infections in children. Clin Infect Dis 2005;40:1785-91
35. Martinez-Aguilar G, Hammerman WA, Mason EO Jr, Kaplan SL. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J 2003;22:593-8
36. Siberty GK, Tekle T, Carroll K, Dick J. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Chem Infect Dis 2003;37:1257-60
37. Fiebelkorn KR, Crawford SA, McElmeel ML, Jorgensen JH. Practical disk diffusion method for detection of inducible clindamycin resistance in Staphylococcus aureus and coagulase-negative staphylococci. J Clin Microbiol 2003;41:4740-4
38. Minuth JN, Holmes TM, Musher DM. Activity of tetracycline, doxycycline, and minocycline against methicillin-susceptible and -resistant staphylococci. Antimicrob Agents Chemother 1974;6:411-4
39. Ruhe JJ, Menon A. Tetracyclines as an oral treatment option for patients with community onset skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2007;51:3298-303
40. Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005;49:2260-6
41. Heldman AW, Hartert TV, Ray SC, et al. Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomised comparison with parenteral therapy. Am J Med 1996;101:68-76
42. Ruis ME, Guerrero IC, Tuazon CU. Endocarditis caused by methicillin-resistant Staphylococcus aureus: treatment failure with linezolid. Clin Infect Dis 2002;35:1018-20
43. Falagas ME, Blisiotis IA, Fragoulis KN. Oral rifampin for eradication of Staphylococcus aureus carriage from healthy and sick populations: a systematic review of the evidence from comparative trials. Am J Infect Control 2007;35:106-14
44. Riedel DJ, Weekes E, Forrest GN. Addition of rifampin in the management of native valve Staphylococcus aureus endocarditis [abstract: L610]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 September 17 - 20; Chicago, USA
45. Peterson LR, Quick JN, Jensen B, et al. Emergence of ciprofloxacin resistance in nosocomial methicillin-resistant Staphylococcus aureus isolates. Resistance during ciprofloxacin plus rifampin therapy for methicillin-resistant S. aureus colonisation. Arch Intern Med 1990;150:2151-5
46. Blumberg HM, Rimland D, Carroll DJ, et al. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. J Infect Dis 1991;163:1279-85
47. Weber SG, Gold HS, Hooper DC, et al. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalised patients. Emerg Infect Dis 2003;9:1415-22
48. Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003 - 04 influenza season. Emerg Infect Dis 2006;12:894-9
49. Kravitz GR, Dries DJ, Peterson ML, Schlievert PM. Purpura fulminans due to Staphylococcus aureus. Clin Infect Dis 2005;40:941-7
50. Francis JS, Doherty MC, Lopatin U, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 2005;40:100-7
51. Hamilton SM, Bryant AE, Carroll KG, et al. In vitro production of Panton-Valentine leukocidin among strains of methicillin-resistant Staphylococcus aureus causing diverse infections. Clin Infect Dis 2007;45:1550-8
52. Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002;359:753-9
53. Lina G, Piemont Y, Godail-Gamot F, et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999;29:1128-32
54. Voyich JM, Otto M, Mathema B, et al. Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease? J Infect Dis 2006;194:1761-70
55. Genestier AL, Michallet MC, Prevost G, et al. Staphylococcus aureus Panton-Valentine leukocidin directly targets mitochondria and induces Bax-independent apoptosis of human neutrophils. J Clin Invest 2005;115:3117-27
56. Labandeira-Rey M, Couzon F, Boisset S, et al. Staphylococcus aureus Panton-Valentine leukocidin causes necrotising pneumonia. Science 2007;315:1130-3
57. Wang R, Braughton KR, Kretschmer D, et al. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat Med 2007;13:1510-4
58. Stevens DL. The role of vancomycin in the treatment paradigm. Clin Infect Dis 2006;42(Suppl 1):S51-7
59. Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006;166:2138-44
60. Lamer C, de Beco V, Soler P, et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993;37:281-6
61. Cruciani M, Gatti G, Lazzarini L, et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996;38:865-9
62. Moise PA, Forrest A, Bhavnani SM, et al. Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health Syst Pharm 2000;57(Suppl 2):S4-9
63. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005;111:e394-434
64. American Thoracic Society/Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and health care-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416
65. Rubinstein E, Cammarata S, Oliphant T, Wunderink R. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: randomized, double-blind, multicenter study. Clin Infect Dis 2001;32:402-12
66. Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003;25:980-92
67. Tsuji BT, Rybak MJ, Cheung CM, et al. Community- and health care-associated methicillin-resistant Staphylococcus aureus: a comparison of molecular epidemiology and antimicrobial activities of various agents. Diagn Microbial Infect Dis 2007;58:41-7
68. Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004;38:1673-81
69. Bowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355:653-65
70. Silverman JA, Mortin LI, Vanpraagh AD, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005;191:2149-52
71. Breedt J, Teras J, Gardovskis J, et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005;49:4658-66
72. Sacchidanand S, Penn RL, Embil JM, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomised, double-blind trial. Int J Infect Dis 2005;9:251-61
73. Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005;41(Suppl 5):S341-53
74. Billeter M, Zervos MJ, Chen AY, et al. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic. Clin Infect Dis 2008;46:577-83
75. Poulakou G, Giamarellou H. Oritavancin: a new promising agent in the treatment of infections due to gram-positive pathogens. Expert Opin Investig Drugs 2008;17:225-43
76. Leonard SN, Rybak MJ. Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections. Pharmacotherapy 2008;28:458-68
77. Jauregui LE, Babazadeh S, Seltzer E, et al. Randomised, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005;41:1407-15
78. Stryjewski ME, O'Riordan WD, Lau WK, et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis 2005;40:1601-7
79. Stryjewski ME, Chu VH, O'Riordan WD, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 2006;50:862-7
80. Sader HS, Fritsche TR, Jones RN. Antimicrobial activities of ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2008;52:1153-5
81. Page MG. Anti-MRSA beta-lactams in development. Curr Opin Pharmacol 2006;6:480-5
82. Noel GJ, Bush K, Bagchi P, et al. A randomised, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 2008;46:647-55
83. Talbot GH, Thye D, Das A, Ge Y. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2007;51:3612-6
84. Stevens DL, Ma Y, Salmi DB, et al. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 2007;195:202-11
85. Zimbelman J, Palmer A, Todd J. Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr Infect Dis J 1999;18:1096-100
86. Schlievert PM, Kelly JA. Clindamycin-induced suppression of toxic-shock syndrome - associated exotaxin production. J Infect Dis 1984;149:471
87. Dickgiesser N, Wallach U. Toxic shock syndrome toxin-1 (TSST-1): influence of its production by subinhibitory antibiotic concentrations. Infection 1987;15:351-3
88. Gemmell CG, Ford CW. Virulence factor expression by Gram-positive cocci exposed to subinhibitory concentrations of linezolid. J Antimicrob Chemother 2002;50:665-72
89. Bernardo K, Pakulat N, Fleer S, et al. Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression. Antimicrob Agents Chemother 2004;48:546-55
90. Stevens DL, Wallace RJ, Hamilton SM, Bryant AE. Successful treatment of staphylococcal toxic shock syndrome with linezolid: a case report and in vitro evaluation of the production of toxic shock syndrome toxin type 1 in the presence of antibiotics. Clin Infect Dis 2006;42:729-30
91. West SK, Plantenga MS. Strausbaugh LJ. Use of decalonisation to prevent staphylococcal infections in various healthcare settings: results of an Emerging Infections Network survey. Infect Control Hosp Epidemiol 2007;28:1111-3
92. Salgado CD, Farr BM, Calfee DP. Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin Infect Dis 2003;36:131-9
93. Kuehnert MJ, Kruszon-Moran D, Hill HA, et al. Prevalence of Staphylococcus aureus nasal colonisation in the United States, 2001 - 2002. J Infect Dis 2006;193:172-9
94. Rim JY, Bacon AE III. Prevalence of community-acquired methicillin-resistant Staphylococcus aureus colonisation in a random sample of healthy individuals. Infect Control Hosp Epidemiol 2007;28:1044-6
95. Farley JE, Ross T, Stamper P, et al. Prevalence, risk factors and molecular epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) nasal colonisation and skin infection among newly arrested males in Baltimore, Maryland [abstract 271]. 46th Annual Meeting of Infectious Diseases Society of America; 2007 October 4 - 7; San Diego, USA
96. Yang ES, Tan J, Rieg G, Miller LG. Body site colonisation prevalence in patients with community-associated methicillin-resistant Staphylococcus aureus infections [abstract 285]. 46th Annual Meeting of infectious Diseases Society of America; 2007 October 4 - 7; San Diego, USA
97. Reagan DR, Doebbeling BN, Pfaller MA, et al. Elimination of coincident Staphylococcus aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment. Ann Intern Med 1991;114:101-6
98. Doebbeling BN, Reagan DR, Pfaller MA, et al. Long-term efficacy of intranasal mupirocin ointment. A prospective cohort study of Staphylococcus aureus carriage. Arch Intern Med 1994;154:1505-8
99. Raz R, Miron D, Colodner R, et al. A 1-year trial of nasal mupirocin in the prevention of recurrent staphylococcal nasal colonisation and skin infection. Arch Intern Med 1996;156:1109-12
100. Ellis MW, Griffith ME, Dooley DP, et al. Targeted intranasal mupirocin to prevent colonisation and infection by community-associated methicillin-resistant Staphylococcus aureus strains in soldiers: a cluster randomised controlled trial. Antimicrob Agents Chemother 2007;51:3591-8
101. Mulvey MR, MacDougall L, Cholin B, et al. Community-associated methicillin-resistant Staphylococcus aureus, Canada. Emerg Infect Dis 2005;11:844-50
102. Cook HA, Furuya EY, Larson E, et al. Heterosexual transmission of community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2007;44:410-3
103. Wendt C, Schinke S, Wurttemberger M, et al. Value of whole-body washing with chlorhexidine for the eradication of methicillin-resistant Staphylococcus aureus: a randomised, placebo-controlled, double-blind clinical trial. Infect Control Hosp Epidemiol 2007;28:1036-43
104. Kaplan SL. Treatment of community-associated methicillin-resistant Staphylococcus aureus infections. Pediatr Infect Dis J 2005;24:457-8
105. Kazakova SV, Hageman JC. Matava M, et al. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med 2005;352:468-75
106. Huijsdens XW, van Santen-Verheuvel MG, Spalburg E, et al. Multiple cases of familial transmission of community-acquired methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2006;44:2994-6
107. Jones TF, Creech CB, Erwin P, et al. Family outbreaks of invasive community-associated methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2006;42:e76-8
108. Zafar U, Johnson LB, Hanna M, et al. Prevalence of nasal colonisation among patients with community-associated methicillin-resistant Staphylococcus aureus infection and their household contacts. Infect Control Hosp Epidemiol 2007;28:966-9
109. Baptiste KE, Williams K, Willams NJ, et al. Methicillin-resistant staphylococci in companion animals. Emerg Infect Dis 2005;11:1942-4
110. Weese JS, Dick H, Willey BM, et al. Suspected transmission of methicillin-resistant Staphylococcus aureus between domestic pets and humans in veterinary clinics and in the household. Vet Microbiol 2006;115:148-55
111. Manian FA. Asymptomatic nasal carriage of mupirocin-resistant, methicillin-resistant Staphylococcus aureus (MRSA) in a pet dog associated with MRSA infection in household contacts. Clin Infect Dis 2003;36:e26-8
112. van Duijkeren E, Wolfhagen MJ, Box AT, et al. Human-to-dog transmission of methicillin-resistant Staphylococcus aureus. Emerg Infect Dis 2004;10:2235-7
113. Rankin S, Roberts S, O'Shea K, et al. Panton valentine leukocidin (PVL) toxin positive MRSA strains isolated from companion animals. Vet Microbiol 2005;108:145-8
114. Johnston CP, Cooper L, Ruby W, et al. Epidemiology of community-acquired methicillin-resistant Staphylococcus aureus skin infections among healthcare workers in an outpatient clinic. Infect Control Hosp Epidemiol 2006;27:1133-6
115. Baggett HC, Hennessy TW, Rudolph K, et al. Community-onset methicillin-resistant Staphylococcus aureus associated with antibiotic use and the cytotoxin Panton-Valentine leukocidin during a furunculosis outbreak in rural Alaska. J Infect Dis 2004;189:1565-73
116. de Boer HE, van Elzelingen-Dekker CM, van Rheenen-Verberg CM, Spanjaard L. Use of gaseous ozone for eradication of methicillin-resistant Staphylococcus aureus from the home environment of a colonised hospital employee. Infect Control Hosp Epidemiol 2006;27:1120-2
117. Wiese-Posselt M, Heuck D, Draeger A, et al. Successful termination of a furunculosis outbreak due to lukS-lukF-positive, methicillin-susceptible Staphylococcus aureus in a German village by stringent decolonisation, 2002 - 2005. Clin Infect Dis 2007;44:e88-95
118. Miller LG, Diep BA. Clinical practice: colonisation, fomites, and virulence: rethinking the pathogenesis of community-associated methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2008;46:752-60
119. McDougal LK, Steward CD, Killgore GE, et al. Pulsed-field gel dectrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J Clin Microbiol 2003;41:5113-20